BioXcel Therapeutics Inc (NASDAQ:BTAI) has a beta value of 0.07 and has seen 0.67 million shares traded in the recent trading session. The company, currently valued at $13.56M, closed the recent trade at $2.24 per share which meant it gained $0.22 on the day or 10.89% during that session. The BTAI stock price is -878.57% off its 52-week high price of $21.92 and 47.77% above the 52-week low of $1.17. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.23 million shares traded. The 3-month trading volume is 277.79K shares.
The consensus among analysts is that BioXcel Therapeutics Inc (BTAI) is Buy stock at the moment, with a recommendation rating of 1.75. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Sporting 10.89% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BTAI stock price touched $2.24 or saw a rise of 0.44%. Year-to-date, BioXcel Therapeutics Inc shares have moved -88.33%, while the 5-day performance has seen it change 11.44%. Over the past 30 days, the shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have changed 26.55%. Short interest in the company has seen 0.32 million shares shorted with days to cover at 0.76.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 77.6% from the levels at last check today.. The projected low price target is $1.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -1016.07% off the targeted high while a plunge would see the stock lose 55.36% from the levels at last check today..
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
The company’s shares have lost -62.89% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 6.20% over the past 5 years. Earnings growth for 2025 is a modest 73.84% while over the next 5 years, the company’s earnings are expected to increase by 53.72%.
BTAI Dividends
BioXcel Therapeutics Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Insiders own 8.65% of the company shares, while shares held by institutions stand at 11.02% with a share float percentage of 12.06%. Investors are also buoyed by the number of investors in a company, with BioXcel Therapeutics Inc having a total of 38.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 2.99 million shares worth more than $3.82 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 1.1178% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 2.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.82 million and represent 0.8252% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 0.30% shares in the company for having 18.33 shares of worth $39961.0 while later fund manager owns 14.23 shares of worth $31019.0 as of May 31, 2025 , which makes it owner of about 0.23% of company’s outstanding stock.
